Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3,4-Dihydro-5-methyl-Isoquinolinone is a small molecule experimental compound belonging to the isoquinolone class. Structurally it is a heterocyclic compound with a benzene ring fused to a pyridone ring and a methyl group at the fifth position[1][2][3]. It acts as an inhibitor of poly [ADP-ribose] polymerase 1 (PARP1), an enzyme involved in DNA repair processes. The compound has demonstrated inhibitory activity against PARP1 with reported IC50 and Ki values of approximately 150 nM and 70 nM respectively[1]. There are no approved indications or clinical trials for this agent; it remains an experimental research tool.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3,4-dihydro-5-methyl-isoquinolinone.